The aberrant high expression of survivin in cancers is a predictive of poor clinical outcome, contributes to both radiotherapy [80] and chemotherapy resistance [81,82,83], and correlates with relapse in various cancers such as bladder cancer [84], non-small cell lung cancer [85], gall bladder carcinoma [86], locally advanced rectal cancer [87], renal cell carcinoma [88], and breast cancer [89,90]. Here, BIRC5 is linked to cancer.